Transmission of rotaviruses occurs by the fecal-oral route, providing a highly efficient mechanism for universal exposure that has circumvented regional and national cultural practice differences. The symptoms associated with rotavirus disease typically are diarrhea and vomiting accompanied by fever, nausea, anorexia, cramping, and malaise that can be mild and of short duration or produce severe dehydration. 5, 6 Severe disease occurs primarily in young children, most commonly among those aged 6 to 24
months. Approximately 90% of children in both developed and developing countries experience a rotavirus infection by the time they reach 3 years of age. tomatic. 12 Recognizing that there might be advantages in developing a vaccine from a human rather than an animal rotavirus strain, multiple cell culture passages were used to attenuate the 89-12 isolate.
This 89-12 isolate was passaged 26 times in primary cells and then seven times in a serially-passaged cell line. 13 The vaccine was then evaluated in phase 1 trials in adults, followed by children with previous rotavirus infections, followed by infants. 13 The vaccine appeared to be safe and efficacy trials followed. In the initial randomized placebo-controlled double blind trial, two oral doses of 89-12 (1x10 5 PFU/mL) were safe although a mild fever of short duration was detected in 19% of vaccinees. 14 Efficacy was 89% against any rotavirus disease and 100% against very severe diseases and infections requiring medical attention. Follow-up of the children continued for a second year and revealed an efficacy of 76% against any rotavirus disease and continued to be 100%
for very severe disease and infection requiring medical intervention. This is now clearly answered in this study and in the larger trial. 17 The outer shell of the rotavirus is composed of the VP7
(also referred to as the G protein) and VP4 (also referred to as the P protein) proteins. Antibodies to these two proteins, and only these two proteins, are capable of neutralizing the virus in vitro. There are at least 14 types of the VP7, with five of them being common in human disease (G1-4 and G9), in There are at least 25 VP4 types, three of which are seen in humans (P [8] , P [4] , and P [6] ). The most common combinations of VP7 and VP4 are G1P [8] , G3P [8] , G4P [8] , G9P [8] G9P [6] , and G2P [4] . True heterologous protection would be against a virus that differs in both of these proteins. Protection by the G1P [8] strain found in Rotarix™ against a G2P [6] infection would be an example of the heterologous protection, while protection of G1P [8] against G3P [8] , G4P [8] and G9 P [8] would not be considered truly heterologous because they share the VP4 protein. Thus, the protection against G9
reported here may have come from the antibodies induced by the vaccine VP4 P [8] against other P [8] rotavirus strains, for example, G9P [8] .
In summary, the trial reported in this journal supports the safety and efficacy of RIX 4414 (Rotarix™) when given with other routine childhood vaccines. Efforts are continuing to evaluate the vaccine in the least developed areas of the world where the vaccine is most needed.
